

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/100897/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Kearney, Anna, Williamson, Paula, Young, Bridget, Bagley, Heather, Gamble, Carrol, Denegri, Simon, Muir, Delia, Simon, Natalie, Stephen, Thomas, Elliot, Jim T., Bulbeck, Helen, Crocker, Joanna C., Planner, Claire, Vale, Claire, Clarke, Mike, Sprosen, Tim and Woolfall, Kerry 2017. Priorities for methodological research on patient and public involvement in clinical. *Health Expectations* 20 (6) , pp. 1401-1410. 10.1111/hex.12583 file

Publishers page: <http://dx.doi.org/10.1111/hex.12583> <<http://dx.doi.org/10.1111/hex.12583>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Title: Priorities for methodological research on patient and public involvement in clinical**
2 **trials: a modified Delphi process**

3 Anna Kearney¹, Paula Williamson², Bridget Young³, Heather Bagley¹, Carrol Gamble², Simon
4 Denegri⁴, Delia Muir⁵, Natalie A. Simon⁶, Stephen Thomas⁷, Jim T. Elliot⁸, Helen Bulbeck⁹, Joanna C.
5 Crocker¹⁰, Claire Planner¹¹, Claire Vale¹², Mike Clarke¹³, Tim Sprosen¹⁴, Kerry Woolfall*

6 *Corresponding author:

7 **Authors**

Commented [KW1]: Please all add qualifications and title

8 Anna Kearney BSc(Hons)_PGCert, Researcher, Clinical Trials Research Centre (CTRC), North West
9 Hub for Trials Methodology/ University of Liverpool, Liverpool, UK, L12 2AP

10 Paula Williamson (Qualifications), Professor, Clinical Trials Research Centre (CTRC), North West Hub
11 for Trials Methodology/ University of Liverpool, Liverpool, UK, L12 2AP

12 Bridget Young (Qualifications) Professor, Department of Psychological Sciences, North West Hub for
13 Trials Methodology/ University of Liverpool, Liverpool, UK, L31 3GL

14 Heather Bagley (Qualifications, Title) Clinical Trials Research Centre (CTRC), North West Hub for
15 Trials Methodology/ University of Liverpool, Liverpool, UK, L12 2AP

16 Simon Denegri (Qualifications, Title) University College London and National Institute for Health
17 Research (NIHR), INVOLVE, UK, London, N1 6DR

18 Carrol Gamble (Qualifications), Professor, Clinical Trials Research Centre (CTRC), North West Hub for
19 Trials Methodology/ University of Liverpool, Liverpool, UK, L12 2AP

20 Delia Muir (Qualifications, Title), Leeds Institute of Clinical Trials Research (LICTR), University of
21 Leeds, Leeds, LS2 9JT, UK

22 Natalie A. Simon (Qualifications, Title) Health Care Research Wales, Public Involvement and
23 Engagement, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, UK, CF11 9AB

24 Stephen Thomas (Qualifications), Patient and Public Involvement partner

25 Jim T. Elliot (Qualifications), Patient and Public Involvement partner

26 Helen Bulbeck (Qualifications), Patient and Public Involvement partner

27 Joanna C. Crocker (Qualifications, Title), Health Experiences Institute, Nuffield Department of
28 Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road,
29 Oxford, OX2 6GG, UK

30 Claire Planner (Qualifications, Title), Centre for Primary Care, University of Manchester, Manchester,
31 M13 9PL, UK

32 Claire Vale (Qualifications, Title), MRC Clinical Trials Unit, University College London, London, WC1E
33 6BT, UK

34 Mike Clarke (Qualifications), Professor, Centre for Public Health, Queen's University of Belfast,
35 Belfast, BT7 1NN, UK

36 Tim Sprosen (Qualifications, Title), Nuffield Department of Population Health, Oxford University,
37 Oxford, OX2 6GG, UK

38 Kerry Woolfall BA (hons), MA (hons), PhD, Research Fellow, Department of Psychological Sciences,
39 North West Hub for Trials Methodology/ University of Liverpool, Liverpool, UK, L31 3GL. Tel: 0151
40 794 4634. Email: K.Woolfall@liverpool.ac.uk

41

42 **Word count:** 4046

Commented [KW2]: Max 5000

43 **Acknowledgements** The online survey was conducted using software designed and developed by
44 Richard Crew and Duncan Appelbe at the CTCRC, University of Liverpool. We would like to thank all
45 the patients and researchers who took part in this study.

46 **Competing interests:** All authors have completed the ICMJE uniform disclosure form and declare: no
47 support from any organisation for the submitted work; no financial relationships with any
48 organisations that might have an interest in the submitted work in the previous three years; and no
49 other relationships or activities that could appear to have influenced the submitted work.

Commented [KW3]: Please let us know if you have any of the listed conflicts of interest and we will edit and complete the ICMJE form.

50 **Contributors** KW, CG, BY and PW conceived the study. KW led the study. PW oversaw statistical
51 analyses. KW, AK, PW, BY, HB, CG, SD, DM, MC and TS designed the study. AK and KW wrote first
52 draft of the manuscript. PW facilitated the consensus meeting. AK reviewed the literature to
53 identify potential topics, organised the survey and consensus meeting and analysed the data under
54 supervision from PW. All authors contributed to the study design, interpretation of data and revised
55 and approved the final manuscript.

56 **Funding** METHODICAL was funded by the MRC Hubs for Trials Methodology Research Network

57 Project Reference: N62

58 **Ethical approval** The IPHS Research Ethics Committee at the University of Liverpool reviewed and

59 granted approval for this research on the 22nd September 2015 (Ref: IPHS-1415-VA-212)

60

ABSTRACT

Commented [WK4]: Max 250 words

Background: Despite increasing international interest, there is a lack of evidence about the most efficient, effective and acceptable ways to implement patient and public involvement (PPI) in clinical trials.


Objective: To identify the priorities of UK PPI stakeholders for methodological research to help resolve uncertainties about PPI in clinical trials.

Design: A modified Delphi process including a two round online survey and a stakeholder consensus meeting.

Participants: ~~We used snowball sampling to identify and invite UK PPI stakeholders to take part in the online Delphi.~~ In total, 237 people registered of whom 219 (92%) completed the first round. 187 of 219 (85%) completed the second; 25 stakeholders attended the consensus meeting.

Results: Round 1 of the survey comprised 36 topics; 42 topics were considered in round 2 and at the consensus meeting. ~~The number and range of topics considered by 70% plus of meeting participants to be critically important indicates the high level of uncertainty and lack of evidence to inform PPI in clinical trials.~~ 96% of meeting participants rated the top three topics as equally important. These were: developing strong and productive working relationships between researchers and PPI contributors; exploring PPI practices in selecting trial outcomes of importance to patients; and a systematic review of PPI activity to improve the accessibility and usefulness of trial information (e.g. participant information sheets) for participants.

Conclusions: The prioritised methodological research topics indicate important areas of uncertainty about PPI in trials. Addressing these uncertainties will be critical to enhancing PPI. Our findings should be used in the planning and funding of PPI in clinical trials to help focus research efforts and minimise waste.



85 **Priorities for methodological research on patient and public involvement in clinical trials:**
86 **a modified Delphi process**

87

88 **INTRODUCTION**

89 Growing awareness of the importance of patient centeredness in research^{1,2} has influenced the
90 establishment of Patient-Centred Outcomes Research Institute (PCORI) in the United States, the
91 National Institute for Health Research (NIHR) INVOLVE organisation in the United Kingdom (UK) and
92 similar bodies elsewhere. These organisations have been at the vanguard of international efforts to
93 involve patients as research partners, alongside researchers, to set research agendas, design studies
94 and decide what outcomes should be measured.^{3,4} The emphasis on patient centeredness in
95 research stems from a belief that involving patients in decisions about how studies are designed and
96 conducted improves research, making it more relevant to end users^{3,5-7} and reducing waste.^{8,9}
97 Patient involvement is also believed important for moral reasons, based on the principle that the
98 people whose lives are most affected by research should have a say. In the UK patient involvement is
99 known as Patient and Public Involvement (PPI).^{5,10} In clinical trials, PPI tends to involve a small
100 number of patients or members of the public (known as PPI contributors).¹¹ Some PPI contributors
101 will have direct personal experience of the condition being investigated, whilst others bring general
102 experience of being a patient or service user. A key consideration is that PPI contributors are in a
103 position to offer a distinctive perspective to researchers or clinicians. Many UK funders require
104 researchers [seeking funding](#) to provide evidence of how PPI will inform their studies.¹²⁻¹⁴

105 Despite the [international](#) emphasis on PPI [in the UK and internationally](#), there are uncertainties
106 about how best to implement it,¹⁵ about the purpose of PPI and whether it actually does improve
107 research.^{10,12,15,16} Concerns have been raised about tokenism and resourcing in PPI, about the
108 difficulty of ensuring diversity and avoiding professionalization among PPI contributors,^{10,17,18}
109 complexities with researchers and patients sharing power,¹⁹ and inadequacies in training and

110 support for both PPI contributors and researchers.²⁰ Problems with the conceptualisation and
111 meaningful assessment and measurement of PPI have also been identified.²¹

112 Each of these concerns points to different priorities for methodological research on PPI. Reviews of
113 ~~PPI in research and other contexts~~ ~~public involvement~~ ~~similarly~~ identify many topics for future
114 research.^{4,21-24} Although not all reviews focus specifically on clinical trials, trials are regarded as
115 particularly likely to benefit from PPI^{20,25} by helping to address the many methodological issues that
116 arise within trials.⁵ Most ~~of these~~ reviews of PPI echo similar concerns to those identified in the
117 above paragraph, pointing to the need for: agreed tools for measuring PPI and its impact across the
118 different phases of research,^{15,24,26,27} for investigations of how best to support PPI^{6,23,28} and for
119 optimal models of implementing PPI.^{29,30} However, many of these topics have been identified by PPI
120 researchers and it is unclear whether these priorities are shared by the wider community of trialists
121 and PPI stakeholders. Given the diversity of stakeholders involved in PPI, there is considerable
122 potential for divergence in the prioritisation of topics to investigate, and therefore for dilution of
123 research efforts in investigating how to improve PPI in research.

124 In the **METHODs** for Patient and Public Involvement In Clinical TriAls (METHODICAL study) we
125 conducted a modified Delphi process to identify the priorities of a broad range of PPI stakeholders
126 for methodological research to resolve uncertainties about PPI in clinical trials, as well as to help
127 improve to the design of future PPI research and avoid unnecessary duplication of research effort.

128

129 **METHODS**

130 Delphis ~~processes~~ are used in health and social science research as a means of involving participants
131 with relevant experience, via ~~in~~ a multi staged study, to achieve consensus on a given topic.^{16,31,32}
132 This involves conducting sequential anonymous surveys to collect, collate and present results back
133 to the group. To help achieve consensus, participants can view and revise their own responses in

134 light of group responses.³² The process can be modified to include opportunities for feedback or a
135 consensus meeting so that participants can discuss their views.^{33,34} We used a modified Delphi,
136 comprising a literature review to identify topics for research on PPI, followed by a two round online
137 survey and stakeholder consensus meeting.

138 We established a study team of 17 PPI stakeholders from across the UK to oversee the METHODOICAL
139 project, including: four PPI Coordinators, eight PPI researchers, one PPI planner, two PPI
140 contributors, one non lay reviewer and one lay reviewer. Seven members of the team had secondary
141 PPI related roles.

142 Patient involvement

143 ~~Patient involvement is central to the aims and purpose of this study.~~ Our study team included three
144 patient partners who were involved in all aspects of study design and conduct, including
145 development of protocol, pilot topics and accompanying text, survey recruitment, interpretation of
146 study findings and review of this manuscript. Approximately half of the consensus meeting places
147 were allocated to patients. We will send study participants a summary of the patient friendly copy of
148 the study study findings. The summary A copy of the findings will also be placed on the study
149 website and promoted through social media platforms used by patients.

150 Recruitment

151 To help maximise the utility of our findings we aimed to include all key paid and unpaid roles of
152 people who co-ordinate, support and contribute to PPI in trials. Individuals were eligible to
153 participate in the Delphi process if they had at least 12 months' experience of PPI in clinical trials.
154 Study team members did not participate in the survey. As definitions of roles in PPI vary, to inform
155 team identified seven stakeholder groups to inform recruitment, in consultation with our PPI
156 to we selected terminology to help define each group (Table 1). A free text field was included at
157 participants could elaborate on their role/s and self-identify their role if they felt this was not

Commented [KW5]: Reviewer 1 comment – this is not needed.
agree

Formatted: Highlight

Formatted: Highlight

Commented [KW6]: To help address the comment that our
language was patronising

Formatted: Highlight

Formatted: Highlight

Commented [KW7]: To help address reviewer 1 comment:
a) What is the rationale for including PPI researchers/coordinators in
the Delphi study, rather than focusing on patients whose priorities
have not yet been as heard?

Commented [KW8]: To address reviewer 1 concerns:

Definitions of the participants are troubling throughout.... it seems
odd to lump them together

I have not responded to the query about how we categorised service
user researchers - as this reviewer was the only service user
researcher who participated. We did add an 'other' category after
issue about categorising service user researchers was raised by the
reviewer at round 1 - I have added this in to explain

158 ~~included in the list.~~ The study team agreed that for the feedback of results in round 2 to be
159 meaningful at the level of stakeholder group, approximately 10 participants per group would be
160 required.

161 [Insert Table 1 here]

162 We used snowball sampling to identify stakeholders.³⁵ ~~This involved the study team~~ using personal
163 contacts and internet searches to develop a database of individuals, organizations and networks
164 under each of the seven stakeholder groups. The METHODICAL researcher (AK) sent emails to ~~the~~
165 ~~identified organisations and networks~~ organisations, networks and individuals (Supplementary file
166 S1) with study information. The email included a request to invite potential survey participants by
167 distributing the study invitation to their members ~~or contacts list or by placing a study advert on~~
168 ~~their website or in a newsletter. Study team members also sent the email invitation to appropriate~~
169 ~~personal contacts with a request to forward the invitation to anyone with relevant experience.~~ AK
170 ~~also~~ placed an advert and link to the survey on the 'People in Research Forum'
171 (www.peopleinresearch.org).

172 Development and pilot of topics

173 We ~~used online search engines (e.g. google scholar and OVID (Medline), organisational databases~~
174 ~~(e.g. INVOLVE library) and hand searches of citations within key articles to identify literature that~~
175 ~~systematically evaluated the scope and impact of PPI within health research~~^{15,20,24} ~~to and~~
176 ~~developed to identify a broad a~~ develop a list of potential methodological research topics for round 1
177 of the Delphi. This was supplemented by ~~a reviewing of~~ recent publications assessing PPI specifically
178 within clinical trials.^{22,23,27,36} For each topic, we developed accompanying descriptive text to help
179 explain these. The study team, including PPI partners reviewed the list of topics and accompanying
180 descriptions to ensure they were distinct and covered known uncertainties and challenges
181 associated with PPI in clinical trials. Methodological research in this context was described to
182 participants in study information materials as: "methods, practices and procedures of patient and

Commented [KA9]: How was the literature identified to inform the development of the Delphi questionnaire? Was this a systematic review? A summary of this evidence indicating the range of stakeholder involvement in generating this evidence would be useful

KW I don't think this (in pink) is necessary- it's a project in itself

183 public involvement (PPI) in clinical trials". We piloted the list of topics with a small group of lay (n=2)
184 and non-lay (n=3) PPI stakeholders to check clarity and understanding and then refined the list of
185 topics and descriptive text. (Figure1)

186 [Insert Figure 1. Overview of the Delphi process]

187

188 **Online survey**

189 The online Delphi was conducted between November 2015 and March 2016. Round one was open
190 for approximately 5 weeks and round two for 4.5 weeks.

191 In round 1, stakeholders registered for the study by indicating their name, email address, which of
192 the seven stakeholder groups they had the most experience in, years length of PPI experience (~~in~~
193 ~~years~~), consent to participate, interest in attending the consensus meeting and interest in receiving a
194 copy of the published findings. We assigned each registered user a unique identifier to ensure
195 anonymity and enable linking of scores between rounds. Participants then scored the importance of
196 each of research topic using a scale of 1-9, with scores 1-3 being not critical or low importance, 4-6
197 important but not critical and 7-9 of critical importance.³⁷ Selecting a score of 10 indicated an
198 abstention from scoring an individual topic. Participants were also invited to suggest additional
199 topics to be added to round 2. Participants who registered but did not start attempt to complete the
200 survey, or partially completed round 1 questions, were excluded from the analysis and not invited
201 for round 2. ~~Partial responders were also excluded, as it is unclear whether their responses were~~
202 ~~their final responses.~~ The study team reviewed additional topics suggested by participants in round 1
203 for inclusion in round 2.

204 In round 2 we showed participants bar charts summarising the distribution of the percentage of
205 scores 1-9 for each topic from each stakeholder group. We then invited participants to revise or
206 keep their own score from the previous round. The email invitation for round 2 indicated that

207 responses received within 10 or 17 days would be entered into prize draws for a £50 voucher or a
208 £30 voucher respectively. AK sent email reminders periodically to non responders.

209 **Consensus meeting**

210 We allocated thirty places to equal numbers of lay and non-lay stakeholders with broad
211 representation across the seven stakeholder groups (~~Table 2~~). The METHODICAL study team were
212 invited to attend and participate in the consensus meeting. Three study team members helped to
213 facilitate the meeting and did not take part. Ten other study team members registered to attend as
214 participating stakeholders and were allocated either lay or non-lay places based on their primary PPI
215 roles. We invited survey participants at random within their stakeholder group. Only survey
216 participants who completed both rounds of the survey and who registered their interest in attending
217 the consensus meeting were eligible to attend.

218 AK emailed each registered attendee a copy of the agenda and their scores from round 2 one week
219 before the meeting. PW, a member of the METHODICAL team, facilitated the meeting due to her
220 previous experience in this role facilitating consensus meetings. Team members KW and AK began
221 the meeting with a short study overview. AK presented the results from round 2 sequentially and in
222 the same order as presented in the online survey. Each topic and accompanying description was
223 presented together with bar charts showing how each stakeholder group had scored each topic. We
224 provided attendees with paper copies of their individual scores and the level of consensus achieved
225 within stakeholder groups during round 2 (Supplementary file S4). PW began by asking attendees if
226 any clarification of the topic was required. Comments and discussion were then encouraged before
227 PW asked attendees to consider whether or not the topic should be prioritised for future research.
228 Where more than 70% of round 2 participants in any one stakeholder group had indicated a topic
229 was of high importance (scored it 7-9), we invited attendees to raise opposing arguments. A similar
230 approach was followed for those topics where less than 50% of round 2 participants in any one
231 group had indicated a topic to be of less importance (scored it 1-3), with views requested if a

Commented [KW10]: Move suggested by a reviewer

232 participant felt strongly that a topic should be considered important. PW encouraged a fuller
233 discussion where the online survey results indicated mixed views on a topic. Following discussion of
234 each topic an anonymous vote was undertaken using a hand held voting device (Turning Point
235 software, version 5). Meeting attendees could abstain from voting for an individual topic by
236 selecting a score of 10. This process was repeated until all topics were discussed and voted on.

237 AK circulated a written report [to meeting attendees](#) seven weeks after the meeting, which included
238 notes from meeting discussions and any changes made to the topic description text.

239 **Statistical Analysis**

240 We pre-defined consensus as 70% or more participants scoring 7 to 9 and less than 15% participants
241 scoring 1 to 3 on a particular topic.^{38,39} All statistical analysis was performed in R version 3.2. We
242 ranked final research topics from the METHODOICAL consensus meeting according to the percentage
243 of participants scoring a research topic as critically important (scores 7-9) and then by ascending
244 order of the percentage of scores 1- 3.

245 **RESULTS**

246 **Online Survey**

247 ~~Response rates by stakeholder group for round 1 and 2 are shown in Table 2.~~ Of the 237 people who
248 registered for the survey, 219 (92%) completed round 1. Twelve individuals registered but did not
249 start the survey and six provided partial responses (Figure 1). All eighteen individuals were excluded
250 from the analysis. Of the 219 who completed round 1, 187 (85%) completed round 2 and were
251 included in the analysis. Of the remaining 32, one withdrew from round 2 of the survey, two died,
252 two partially completed round 2, and 27 did not complete any part. [Completion rates by stakeholder](#)
253 [group for round 1 and 2 are shown in Table 2.](#) Round 1 of the survey comprised 36 methodological
254 research topics (Supplementary file S2). The study team reviewed 81 additional research topics

255 suggested by survey participants. Of these, we agreed that 46 suggestions were within the scope of
256 existing topics, although we added additional examples to seven existing topics or descriptors to
257 improve their clarity. Twenty eight suggestions contributed to the development of six new topics
258 which were added to round 2. The remaining seven suggestions related to trial participants not PPI
259 and were therefore considered to be out of scope. However, these led to the inclusion of a new
260 topic aimed at exploring the definition of PPI and people's understanding of it. Round 2 of the survey
261 comprised of 42 methodological research topics, including the six new topics created from
262 participant suggestions.

263 ~~At the end of round 2 w~~We reviewed results against the definition of consensus agreed at the
264 beginning of the study. At the end of round 2 there was no consensus across all stakeholder groups
265 as to which research topics were of critical importance. Only three topics achieved consensus across
266 six of the seven groups (Supplementary file S4).

267 **Consensus Meeting**

268 Of the 30 people registered, 25 ~~people~~ attended ~~the meeting~~ and were eligible to vote (Table 2).
269 Seventeen were survey participants and eight members of the METHODICAL study team. Twelve
270 (48%) attendees were lay and 13 (52%) were non-lay. Although no attendees identified PPI advisor
271 as the stakeholder group that they most identified with, at least two had PPI advisor roles; all
272 stakeholder groups were therefore represented at the meeting.

273 [Insert Table 2 here]

274 All 42 topics were discussed and voting was undertaken on all except two, topics 38 and 39.
275 Following discussion attendees concluded that topic 38 (methods to measure PPI impact) should be
276 subsumed within topic 37 (core outcomes to evaluate PPI), while topic 39 (characteristics of PPI
277 which lead to a successful trial) was considered to be too broad. We made changes to three topic

Commented [KW11]: Moved from methods to results section

278 titles and nine [descriptive help](#) texts after group discussion in order to clarify the topic before voting
279 (Supplementary file S2).

280 The supplementary file S3 provides the final ranked list of all research topics. Sixteen topics achieved
281 consensus with greater than 70% of participants scoring them 7-9 and less than 15% scoring them 1-
282 3. As shown in Table 3 the top ten prioritised research topics were varied, covering PPI processes,
283 resources, practices and relationships between stakeholder groups. Three topics shared joint 'first
284 place' with 96% of meeting attendees rating each as critically important: developing strong and
285 productive working relationship between researchers and PPI contributors; PPI practices in selecting
286 trial outcomes of importance to patients; and a systematic review of PPI activity in improving the
287 accessibility and usefulness of trial information (e.g. leaflets and information sheets) for clinical trial
288 participants.

289 [Insert Table 3 Here]

290 As discussed previously, an additional topic, regarding the definition of PPI and people's
291 understanding of it, was added to round 2. Attendees gave low ratings for this topic, commenting
292 that improved communication about the definition of PPI was needed within the trials community
293 rather than more research on this definition. Of the six topics suggested by survey participants, only
294 one (Topic 13: Exploring the role of PPI in the early stages of testing of new treatments [e.g. Phase 1
295 and Phase 2 trials]) reached consensus among meeting attendees (Supplementary file S3).

296

297 **DISCUSSION**

298 Through a consensus building process we have identified priority topics for methodological research
299 to inform PPI in clinical trials. The prioritised research topics were varied, covering PPI processes,
300 resources, practices and relationships between stakeholder groups. The number and range of topics
301 considered by more than 70% of meeting participants to be critically important indicates the high

Commented [KW12]: .

302 level of uncertainty and lack of evidence to inform PPI in clinical trials.^{2,4,23,27} Meeting attendees
303 were virtually unanimous about the most important PPI research priorities, with the top six
304 achieving over 92% consensus.

305 Several of the top ten prioritised research topics address concepts that are fundamental to PPI in
306 clinical trials, such as productive working relationships, resources and how to adapt PPI models to
307 avoid a one size fits all approach.³⁰ Previous studies of PPI in clinical trials, have particularly
308 highlighted the importance of productive working relationships in creating the sort of environment
309 to enable contributors to make a difference to research,^{27,40,41} whilst Barber et al, recommended
310 considering PPI as a dynamic partnership rather than a procedural activity.¹⁷ During the consensus
311 meeting many stakeholders shared examples of poor relationships between PPI contributors and
312 researchers, also reflecting the high priority placed on the development of strong and productive
313 partnerships between researchers and PPI contributors.

314 Whilst online resources such as INVOLVE provide costing tools for planning PPI, publications are
315 poor at reporting the true costs.⁴² Topic 9 (resources needed for PPI activity), highlights uncertainties
316 around PPI costs and points to concerns regarding the adequacy of funding to meet these costs.

317 Research is therefore needed to help identify what level of resource is required for the
318 implementation of PPI to ensure PPI plans for such involvement in trials are realistic and adequately
319 supported. Whilst work is being undertaken to develop frameworks and guidelines to guide PPI
320 practice in research,⁴³⁻⁴⁵ PPI plans and activities often vary according to context.²³ Two of the top ten
321 prioritised topics (Topics 4 and 2) point to concerns about current models of PPI,^{29,30} highlighting the
322 need for research to explore look at how to adapt ations of PPI to the needs of particular trials, as
323 well as methods to capture wider patient and public perspectives. For example, concerns were
324 raised about current models of PPI being tokenistic, due to often small numbers (one or two) PPI
325 contributors working on each seeking to share a lay perspective on trials.^{10,17,18} Research is needed

326 to evaluate the effectiveness of different methods to increase diversity and capture wider patient or
327 public perspectives on clinical trial designs, such as online surveys and social media.

328 Some of the top ten topics focus on the impact of PPI and particularly the need to review PPI in
329 specific trial processes, such as: the development of trial information for patients; recruitment and
330 retention of patients; choice and measurement of outcomes; and the dissemination of results. Two
331 of these (Topic 28, strategies to recruit and retain patients, and Topic 29, the selection of trial
332 outcomes) align with existing methodological research agendas for clinical trials.³⁸ Conceptually, PPI
333 should have a substantial role in addressing these issues. However, our results demonstrate that
334 further work is needed to map and formally evaluate current PPI practices to help make these more
335 relevant to ~~patients end users, which in this context are the patients who are invited to participate in~~
336 trials,^{3,5-7} and ~~help to reduce research waste by targeting resources more effectively~~ ~~reduce waste.~~^{8,9}

337 For example, it is common to involve patients in developing information materials for prospective
338 trial participants⁴³ yet it is unclear whether or how this input increases participation rates or
339 improves patient experience of research.²⁰ A systematic review of PPI activity in the development of
340 information materials for prospective trial participants (Topic 31) may provide evidence of the
341 impact of such work, as well as inform future PPI in this important aspect of trial development.

342 During the consensus meeting some prioritised topics were revised to define a research method to
343 be used to explore that particular topic, such as Topic 31: *A systematic review of PPI activity in*
344 *improving accessibility and usefulness of trial leaflets and information sheets for clinical trial*
345 *participants*, whilst others, such as Topic 20 *Developing strong and productive working*
346 *relationships between researchers and PPI contributors* are more ~~wide-ranging general~~ and relate to
347 challenges in PPI. Such ~~wider broader~~ topics may contain multiple components, and further
348 consideration will be needed to develop these topics into formal research questions and to identify
349 the most appropriate research methods for addressing these questions.³²

350

351 Our study had several strengths. The METHODICAL team included representation of all stakeholder
352 groups including lay and non-lay members, who oversaw all stages of the project, including the
353 recruitment strategy. The survey sample size was also relatively large compared to other Delphi
354 studies and ~~the attrition rate was low, with those taking part in round 1 likely to complete round 2.~~
355 Comparison of round one mean scores between those who did and did not complete round two
356 indicate that our study was not affected by attrition bias (Supplementary file S5).

357 We took ~~several a number of~~ steps to help ensure that all stakeholder groups were represented at
358 every stage of the Delphi and that all groups and individuals felt able to contribute freely. We
359 sampled stakeholders purposively for the survey stage. For the consensus meeting a random
360 selection of participants within groups ensured balance and fairness in the allocation places for lay
361 and non-lay stakeholders across all seven of stakeholder groups. ~~Care was taken in the~~ facilitation of

362 ~~the meeting to ensure that all attendees had an equal opportunity to contribute to discussions.~~

363 High and low priority topics identified in our study are cited in international literature on public and
364 patient involvement in research⁴⁶⁻⁴⁸. However, further research is required to explore the level of
365 priority given to these topics in international settings.

366 The study also had some limitations. As the potential sample was large and diverse we were unable
367 to fully define the sampling frame and used snowball sampling to try to make sure all stakeholder
368 groups were included in the sample. As a result, our study was subject to self-selection bias among
369 those who registered for the study. Some study team members participated in the consensus
370 meeting, which meant that a sub-set of attendees were not independent from the project. We
371 reasoned that they would bring valuable experience and expertise to the discussion⁴⁹ and therefore
372 included them in the meeting. To promote transparency, at the beginning of the meeting all
373 attendees introduced themselves and stated whether they took part in the survey, or whether they
374 were a member of the study team. ~~Care was taken in the~~ facilitation of the meeting to ensure that
375 ~~all attendees had an equal opportunity to contribute to~~ discussions. To help attendees feel free to

Formatted: Highlight

Commented [KW13]: Moved this to help address the issue about the team attending and how the meeting

376 vote as they wished during the meeting, voting was anonymous. However, as we did not track
377 individual votes during the meeting, we are unable to present consensus meeting voting data by
378 stakeholder group, or assess how individual scores differed from the online survey.

379 ~~The Delphi process is are~~ dependent upon the participants having time to commit to the process to
380 ~~until it is completion~~.⁵⁰ To reduce the potential burden on participants and minimise attrition bias
381 we choose a two round, rather than a three or four round survey.^{33,51,52} While consensus was not
382 achieved in the two round survey, it was achieved at the meeting, which highlights the value of face
383 to face discussion and collective deliberation in reaching consensus.

384 Rather than beginning with an open question about possible topics and inviting suggestions from
385 participants, the list of topics presented in round 1 was derived from the existing literature.⁵³
386 However, we also invited participants to suggest additional topics in round 1. Despite a large
387 number of suggested topics, relatively few new topics were suggested. Indeed, the majority of topics
388 put forward by participants were already encompassed by existing topics. This perhaps indicates
389 that our approach of presenting a list of topics in round 1 was an appropriate way of conducting a
390 methodological research priority setting exercise in a context where not all stakeholders would be
391 familiar with the concept of methodological research and might struggle to identify priorities
392 without some examples as prompts.

393

394 **CONCLUSIONS**

395 In conclusion, the prioritised methodological research topics identified by the Delphi process
396 highlight key uncertainties about PPI in trials. Addressing these uncertainties will be critical to
397 enhancing PPI. Our findings should be used by those involved in planning and funding of PPI in
398 clinical trials to help focus research efforts and minimise waste.

399

400

401
402

403

404 REFERENCES

405

- 406 1. Ioannidis JPA. Why Most Clinical Research Is Not Useful. *PLoS Med.*
407 2016;13(6):e1002049.
- 408 2. Mullins CD, Vandigo JE, Zheng J, Wicks P. Patient-centeredness in the design of
409 clinical trials. *Value in health : the journal of the International Society for*
410 *Pharmacoeconomics and Outcomes Research.* 2014;17(4):471-475.
- 411 3. Frank L, Basch E, Selby JV, For the Patient-Centered Outcomes Research I. The pcori
412 perspective on patient-centered outcomes research. *JAMA.* 2014;312(15):1513-
413 1514.
- 414 4. Sacristán JA, Aguarón A, Avendaño-Solá C, et al. Patient involvement in clinical
415 research: why, when, and how. *Patient preference and adherence.* 2016;10:631-640.
- 416 5. INVOLVE. INVOLVE Strategy 2012-2015. Putting people first in research. 2012.
- 417 6. Boote JD, Twiddy M, Baird W, Birks Y, Clarke C, Beever D. Supporting public
418 involvement in research design and grant development: a case study of a public
419 involvement award scheme managed by a National Institute for Health Research
420 (NIHR) Research Design Service (RDS). *Health Expectations.* 2015;18(5):1481-1493.
- 421 7. Health Research Authority, INVOLVE. Public involvement in research: impact on
422 ethical research. 2016; [http://www.hra.nhs.uk/documents/2016/05/impact-public-
423 involvement-ethical-aspects-research-updated-2016.pdf](http://www.hra.nhs.uk/documents/2016/05/impact-public-involvement-ethical-aspects-research-updated-2016.pdf).
- 424 8. Salman RA-S, Beller E, Kagan J, et al. Increasing value and reducing waste in
425 biomedical research regulation and management. *The Lancet.* 2014;383(9912):176-
426 185.
- 427 9. Ioannidis JPA, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in
428 research design, conduct, and analysis. *The Lancet.* 2014;383(9912):166-175.
- 429 10. Staniszewska S, Thomas V, Seers K. Patient and public involvement in the
430 implementation of evidence into practice. *Evid Based Nurs.* 2013;16(4):97.
- 431 11. Woolfall K, Young B, Frith L, et al. Doing challenging research studies in a patient-
432 centred way: a qualitative study to inform a randomised controlled trial in the
433 paediatric emergency care setting. *BMJ Open.* 2014;4(5).
- 434 12. Robinson L, Newton J, Dawson P. Professionals and the public: power or partnership
435 in health research? *Journal of Evaluation in Clinical Practice.* 2012;18(2):276-282.
- 436 13. Trust W. Top Tips for Success. 2014.
- 437 14. NIHR. Preparing for a full application for the Clinical Trials and Evaluation Board.
438 2014; [http://www.nets.nihr.ac.uk/
439 data/assets/pdf_file/0003/77160/Preparing-a-
440 full-application-for-the-Clinical-Trials-and-Evaluation-Board.pdf](http://www.nets.nihr.ac.uk/data/assets/pdf_file/0003/77160/Preparing-a-full-application-for-the-Clinical-Trials-and-Evaluation-Board.pdf).
- 441 15. Brett J, Staniszewska S, Mockford C, et al. Mapping the impact of patient and public
442 involvement on health and social care research: a systematic review. *Health
443 Expectations.* 2014;17(5):637-650.
- 444 16. Snape D, Kirkham J, Preston J, et al. Exploring areas of consensus and conflict around
445 values underpinning public involvement in health and social care research: a
446 modified Delphi study. *BMJ Open.* 2014;4(1).
- 447 17. Barber R, Boote JD, Parry GD, Cooper CL, Yeeles P, Cook S. Can the impact of public
448 involvement on research be evaluated? A mixed methods study. *Health expectations
449 : an international journal of public participation in health care and health policy.*
2012;15(3):229-241.

- 450 18. El Enany N, Currie G, Lockett A. A paradox in healthcare service development:
451 professionalization of service users. *Social science & medicine (1982)*. 2013;80:24-30.
- 452 19. Boote JD, Dalglish M, Freeman J, Jones Z, Miles M, Rodgers H. 'But is it a question
453 worth asking?' A reflective case study describing how public involvement can lead to
454 researchers' ideas being abandoned. *Health expectations : an international journal of
455 public participation in health care and health policy*. 2014;17(3):440-451.
- 456 20. Staley K. *Exploring Impact: Public Involvement in the NHS, public health and social
457 care research*. 2009.
- 458 21. Staniszewska S, Adebajo A, Barber R, et al. Developing the evidence base of patient
459 and public involvement in health and social care research: the case for measuring
460 impact. *International Journal of Consumer Studies*. 2011;35(6):628-632.
- 461 22. Buck D, Gamble C, Dudley L, et al. From plans to actions in patient and public
462 involvement: qualitative study of documented plans and the accounts of researchers
463 and patients sampled from a cohort of clinical trials. *BMJ Open*. 2014;4(12):e006400.
- 464 23. Gamble C, Dudley L, Allam A, et al. Patient and public involvement in the early stages
465 of clinical trial development: a systematic cohort investigation. *BMJ Open*. 2014;4(7).
- 466 24. INVOLVE. Breaking Boundaries review of public involvement in the NIHR- Update.
467 2014; [http://www.nihr.ac.uk/documents/about-NIHR/NIHR-
468 Publications/Extra%20Mile2.pdf](http://www.nihr.ac.uk/documents/about-NIHR/NIHR-Publications/Extra%20Mile2.pdf). Accessed 02/09/2016.
- 469 25. Oliver S, Armes D, Gyte G. Public Involvement in Setting a National Research Agenda.
470 *Patient-Patient-Centered-Outcome-Res*. 2009;2(3):179-190.
- 471 26. S D. NIHR Strategic Review of Public Involvement in research-"Breaking Boundaries"
472 Keynote speech. Paper presented at: INVOLVE 2014: Changing Landscapes
473 Conference2014; Birmingham, UK.
- 474 27. Dudley L, Gamble C, Preston J, et al. What Difference Does Patient and Public
475 Involvement Make and What Are Its Pathways to Impact? Qualitative Study of
476 Patients and Researchers from a Cohort of Randomised Clinical Trials. *PLoS ONE*.
477 2015;10(6):e0128817.
- 478 28. Fleurence RL, Forsythe LP, Lauer M, et al. Engaging Patients and Stakeholders in
479 Research Proposal Review: The Patient-Centered Outcomes Research
480 Institute Engaging Patients and Stakeholders in Research Proposal Review. *Annals of
481 Internal Medicine*. 2014;161(2):122-130.
- 482 29. Mathie E, Wilson P, Poland F, et al. Consumer involvement in health research: a UK
483 scoping and survey. *International Journal of Consumer Studies*. 2014;38(1):35-44.
- 484 30. South A, Hanley B, Gafos M, et al. Models and impact of patient and public
485 involvement in studies carried out by the Medical Research Council Clinical Trials
486 Unit at University College London: findings from ten case studies. *Trials*.
487 2016;17(1):1-13.
- 488 31. Sinha IP, Smyth RL, Williamson PR. Using the Delphi Technique to Determine Which
489 Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a
490 Systematic Review of Existing Studies. *PLoS Med*. 2011;8(1):e1000393.
- 491 32. Kouyoumdjian FG, Schuler A, McIsaac KE, et al. Using a Delphi process to define
492 priorities for prison health research in Canada. *BMJ Open*. 2016;6(1).
- 493 33. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a
494 research methodology for nursing. *International Journal of Nursing Studies*.
495 2001;38(2):195-200.

- 496 34. Walker MA, Selfe MJ. The Delphi method: a useful tool for the allied health
497 researcher. *British Journal of Therapy and Rehabilitation*. 1996;3(12):677-681.
- 498 35. Sadler GR, Lee H-C, Lim RS-H, Fullerton J. Research Article: Recruitment of hard-to-
499 reach population subgroups via adaptations of the snowball sampling strategy.
500 *Nursing & Health Sciences*. 2010;12(3):369-374.
- 501 36. Dudley L, Gamble C, Allam A, et al. A little more conversation please? Qualitative
502 study of researchers' and patients' interview accounts of training for patient and
503 public involvement in clinical trials. *Trials*. 2015;16(1):1-15.
- 504 37. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and
505 deciding on important outcomes. *Journal of Clinical Epidemiology*. 2011;64(4):395-
506 400.
- 507 38. Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P. The trials methodological
508 research agenda: results from a priority setting exercise. *Trials*. 2014;15(1):32.
- 509 39. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for
510 clinical trials: issues to consider. *Trials*. 2012;13(1):1-8.
- 511 40. Wilson P, Mathie E, Keenan J, et al. ReseArch with Patient and Public invOlvement: a
512 RealisT evaluation –the RAPPORT study. *Health Services and Delivery Research*.
513 2015;3(38).
- 514 41. Evans D, Coad J, Cottrell K, et al. Public involvement in research: assessing impact
515 through a realist evaluation. *Health Services and Delivery Research*. 2014;2(36).
- 516 42. Mockford C, Staniszewska S, Griffiths F, Herron-Marx S. The impact of patient and
517 public involvement on UK NHS health care: a systematic review. *Int J Qual Health
518 Care*. 2012;24(1):28-38.
- 519 43. Bagley HJ, Short H, Harman NL, et al. A patient and public involvement (PPI) toolkit
520 for meaningful and flexible involvement in clinical trials – a work in progress.
521 *Research Involvement and Engagement*. 2016;2(1):1-14.
- 522 44. Pollard K, Donskoy AL, Moule P, Donald C, Lima M, Rice C. Developing and evaluating
523 guidelines for patient and public involvement (PPI) in research. *Int J Health Care Qual
524 Assur*. 2015;28(2):141-155.
- 525 45. INVOLVE. Public involvement in research: values and principles framework,.
526 INVOLVE: Eastliegh2015.
- 527 46. Shippee ND, Domecq Garces JP, Prutsky Lopez GJ, et al. Patient and service user
528 engagement in research: a systematic review and synthesized framework. *Health
529 Expectations*. 2015;18(5):1151-1166.
- 530 47. Nilsen ES, Myrhaug HT, Johansen M, Oliver S, Oxman AD. Methods of consumer
531 involvement in developing healthcare policy and research, clinical practice guidelines
532 and patient information material. *The Cochrane Database Of Systematic Reviews*.
533 2006(3):CD004563.
- 534 48. Domecq JP, Prutsky G, Elrayah T, et al. Patient engagement in research: a systematic
535 review. *BMC Health Services Research*. 2014;14(1):89.
- 536 49. Goodman CM. The Delphi technique: a critique. *Journal of Advanced Nursing*.
537 1987;12(6):729-734.
- 538 50. Buck AJ, Meir G, Hakim S, Weinblatt J. Using the Delphi Process to Analyze Social
539 Policy Implementation: A Post Hoc Case from Vocational Rehabilitation. *Policy
540 Sciences*. 1993;26(4):271-288.
- 541 51. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and
542 guidelines for use. *American Journal of Public Health*. 1984;74(9):979-983.

- 543 52. Sumsion T. The Delphi Technique: An Adaptive Research Tool. *The British Journal of*
544 *Occupational Therapy*. 1998;61(4):153-156.
- 545 53. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey
546 technique. *Journal of Advanced Nursing*. 2000;32(4):1008-1015.
- 547
- 548
- 549

Table 1: Stakeholder Groups for the Delphi process

Stakeholder Group	Definition and examples
PPI Contributors	Patient representatives, research partners in clinical trials
Lay Reviewers	Members of the public sitting on clinical trial funding boards or Research Ethics Committees (RECs)
PPI Coordinators	Roles within a Clinical Trial Unit (CTU) or research network to coordinate PPI activity and PPI contributors and research partners in trials
PPI Advisors	Roles offering advice on how to design and deliver PPI activity within trials. This predominantly includes member of the National Institute for Health Research (NIHR) Research Design Service (RDS)
PPI Planners	Chief Investigators, trial managers and other researchers/staff who plan or oversee PPI in individual trials
PPI Researchers	People who conduct research into PPI in clinical trials and authors of PPI guidance documents
Non-lay Reviewers	Professional members of clinical trial funding boards or Research Ethics Committees (RECs)

Table 2: Stakeholder representation within the survey and at the meeting

Stakeholder group	No. of people (% of stakeholders from previous round ^a)								
	Registered	Completed round 1	% of registered who completed round 1	Completed round 2	% of people from round 1 who completed round 2	Accepted invitation to the meeting	% of round 2 completers who accepted invitation	Meeting attendees	% of people invited to the meeting who attended
Lay reviewers	51	48	94%	39	81%	7	18%	6	86%
PPI contributors	37	36	97%	27	75%	8	30%	6	75%
Total Lay	88	84	95%	66	79%	15	23%	12	80%
Non-lay reviewers	40	38	95%	33	87%	3	9%	3	100%
PPI Planners	53	47	89%	39	83%	4	10%	4	100%
PPI advisors	13	12	92%	12	100%	1	8%	0 ^b	0%
PPI coordinators	26	25	96%	25	100%	4	16%	4	100%
PPI researchers	17	13	76%	12	92%	3	25%	2	67%
Total Non-lay	149	135	91%	121	90%	15	12%	13	87%
TOTAL	237	219	92%	187	85%	30	16%	25	83%

Legend: ^a For example the percentage of Lay reviewers who registered and completed round 1 (94%) is the number who completed (n=48) divided by the number registered (n=51) ^b At least two people with secondary roles of PPI advisor were present at the consensus meeting.

Stakeholder group	No. Registered	No. who completed round 1 (% of registered ^a)	No. who completed round 2 (% of round 1)	No. who accepted the meeting invitation (% of round 2 completers)	No. of meeting attendees (% of those invited)
Lay reviewers	51	48 (94%)	39 (81%)	7 (18%)	6 (86%)
PPI contributors	37	36 (97%)	27 (75%)	8 (30%)	6 (75%)
Total Lay	88	84 (95%)	66 (79%)	15 (23%)	12 (80%)
Non-lay reviewers	40	38 (95%)	33 (87%)	3 (9%)	3 (100%)
PPI Planners	53	47 (89%)	39 (83%)	4 (10%)	4 (100%)
PPI advisors	13	12 (92%)	12 (100%)	1 (8%)	0 ^b (0%)
PPI coordinators	26	25 (96%)	25 (100%)	4 (16%)	4 (100%)
PPI researchers	17	13 (76%)	12 (92%)	3 (25%)	2 (67%)
Total Non-lay	149	135 (91%)	121 (90%)	15 (12%)	13 (87%)
TOTAL	237	219 (92%)	187 (85%)	30 (16%)	25 (83%)

Commented [KA14]: I wonder if this is a clearer way to present the table given the formatting requirements?

Table 3: Top 10 Methodological priorities for PPI in clinical trials

Ranking	Topic No.	Topic Title	Help text	% of meeting scores	
				7-9	1-3
1	TOPIC 20	Developing strong and productive working relationships between researchers and PPI contributors	Research on what defines and enables a good working relationship between researchers on a trial team, trial committee (e.g. trial steering committee or ethics committee) or funding panels and PPI contributors? Exploring the impact of role descriptions, selection criteria, clear expectations, language, communication and handling conflict.	96%	0%
1	TOPIC 29	PPI practices in selecting trial outcomes of importance to patients	A review of PPI practices that influence the primary outcomes within clinical trials e.g. seizure control at 6 months, time to healing. How often are these outcomes that are of importance to patients, and what role did PPI play in the decision making process?	96%	0%
1	TOPIC 31	A systematic review of PPI activity in improving the accessibility and usefulness of trial leaflets and information sheets for clinical trial participants	Patient/public contributors often help trial teams to design and produce information sheets. An assessment of existing research to evidence how PPI impacts patients understanding and acceptability of PIS within trials? How do PPI contributors write or review Patient Information Sheets? How often are they given guidance for this? Do trial teams listen to the advice of PPI contributors, how often are their changes adopted?	96%	0%
4	TOPIC 4	Adapting PPI to the particular needs of individual clinical trials	Research on how to tailor PPI plans to take into account key design features or specific patient groups e.g. critically ill patients or children, including how the needs of clinical trials for PPI might change over the life of a trial. For example would a specific type of trial benefit from the use of patient panels rather than having one or two lay members on the trial steering committee?	92%	0%
4	TOPIC 9	The resources needed for PPI activity including time and money.	What are the resource implications for undertaking PPI? Do resource limitations impact upon PPI activity? What is spent on PPI activity for grant applications? How much budget is allocated within trials, what does it actually cost and is it possible to quantify the benefits in monetary terms? Evaluating current payment systems upon Involvement of PPI contributors at all stages of a trial.	92%	0%
4	TOPIC 28	PPI practices to address the challenges of recruiting and retaining participants (e.g. patients) in clinical trials	Exploring the effectiveness of PPI practices to improve recruitment of patient participants (i.e. the people taking part as 'subjects' in clinical trials), or help keep patients within a trial.	92%	0%
7	TOPIC 30	PPI practices in selecting how to measure trial outcomes	A review of how PPI is used to decide on how outcomes are measured. For example how does PPI contribute to deciding whether a trial should collect data from patients using a weekly diary or a monthly questionnaire?	88%	0%

Commented [KA15]: Check text as noted doesn't make sense. Typor?

Ak – the reviewer is right it has too many words. However, I think this is what was used in the survey. Do we correct now or leave it?

Commented [WK16]: I think this slight amendment is ok as it matches the main description in the left hand column-

8	TOPIC 35	How is PPI involved in the dissemination of results and assessment of effectiveness?	A review of how PPI contributors are involved in writing lay reports for patient organisations or trial participants and presenting findings at conferences. Does involving PPI contributors impact on the effectiveness of dissemination? How often are funds available for this PPI work?	84%	0%
9	TOPIC 22	How do PPI contributors achieve and maintain an authentic patient perspective?	How does personal experience along with social demographics shape the perspective and input of a PPI contributor? Do PPI contributors become “professionalised” (i.e. more like researchers) over time? What helps to avoid this and keep them “in touch” with the authentic patient perspective? Do PPI contributors collect feedback from members of the public/ other patients to help them in their role? If so what methods do they use and are they effective?	84%	12%
10	TOPIC 2	Effectiveness of different methods to capture wider patient or public perspectives on clinical trial designs e.g. surveys, social media	PPI traditionally involves one person or small numbers of patients or public representatives seeking to share a ‘lay perspective’ on trials. This research would look at ways to involve larger numbers of people in PPI within clinical trials.	80%	0%
10	TOPIC 33	What is the impact of PPI activity on the experience of patients who participate in a clinical trial?	Assessing the impact of PPI activity on a patients’ experience of trial participation, including their experience of consent, treatment, follow up and communication of the results.	80%	0%